Idazoxan and Response to Typical Neuroleptics in Treatment-Resistant Schizophrenia: Comparison with the Atypical Neuroleptic, Clozapine

British Journal of Psychiatry

Volumn 168, Issue MAY, 1996, Pages 571-579

  Litman, Robert E ^a   Su, Tung Ping ^a   Potter, William Z ^a   Hong, Walter W ^a   Pickar, David ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; BENZATROPINE; CLOZAPINE; FLUPHENAZINE; IDAZOXAN; NEUROLEPTIC AGENT; THIORIDAZINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EXTRAPYRAMIDAL SYNDROME; FEMALE; HUMAN; SCHIZOPHRENIA;

ADRENERGIC ALPHA-ANTAGONISTS; ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DIOXANES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FLUPHENAZINE; HUMANS; IDAZOXAN; IMIDAZOLES; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 0029949349     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/bjp.168.5.571     Document Type: Review

References (26)

1. AMERICAN PSYCHIATRIC ASSOCIATION (1987) Diagnostic and Statistical Manual of Mental Disorders (3rd edn, revised) (DSM-III-R). Washington, DC: APA.
2. ANDREASEN, N. C. (1981) The Scale for the Assessment of Negative Symptoms (SANS). Iowa City: University of Iowa.
3. BREIER, A., BUCHANAN, R. W., WALTRIP III, R. W., et al (1994) The effect of clozapine on plasma norepinephrine: relationship to clinical efficacy. Neuropsychopharmacology, 10, 1-7.
4. BUNNEY, W. E. JR. & HAMBURG, D. A. (1963) Methods for reliable longitudinal assessment of behaviour. Archives of General Psychiatry, 9, 280-294.
5. DAVIDSON, M., KAHN, R. S., STERN, R. G., et al (1993) Treatment with clozapine and its effect on plasma homovanillic acid and norepinephrine concentrations in schizophrenia. Psychiatry Research, 46, 151-163.
6. 2/1C antagonist, and negative symptoms in schizophrenia: a placebo-controlled, double-blind trial. British Journal of Psychiatry, 163, 451-455.
7. EISENHOFER, G., GOLDSTEIN, D. S., STULL, R., et al (1986) Simultaneous liquid chromatographic determination of 3,4-dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma in their responses to inhibition of monoamine oxidase. Clinical Chemistry, 32, 2030-2033.
8. GREEN, A. I., ALAM, M. Y., SOBIERAJ, J. T., et al (1993) Clozapine response and plasma catecholamines and their metabolites. Psychiatry Research, 46, 139-149.
9. GRENHOFF, J., NISSEL, M., FERRE, S., et al (1993) Noradrenergic modulation of midbrain dopamine cell firing elicited by stimulation of the locus coeruleus in the rat. Journal of Neural Transmission, 93, 11-25.
10. GUY, W. (1976) ECDEU Assessment Manual for Psychopharmacology, pp. 535-543. Rockville, MD: Alcohol, Drug Abuse, and Mental Health Administration.
11. JAVAID, J. I., DEKIRMENJIAN, H., LISKEVYCH, U., et al (1981) Fluphenazine determination in human plasma by sensitive gas chromatographic method using a nitrogen detector. Journal of Chromatographic Sciences, 19, 439.
12. KANE, J., HONIGFELD, G., SINGER, J., et al (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind placebo comparison with chlorpromazine. Archives of General Psychiatry, 45, 789-796.
13. KAROUM, F. & NEFF, N. (1982) Quantitative gas chromatography-mass spectrometry (GC-MS) of biogenic amines: theory and practice. In Modern Methods in Pharmacology (eds S. Spector & N. Beck), pp. 131-163. New York: Alan R. Liss.
14. LITMAN, R. E., HONG, W. W., WEISSMAN, E. M., et al (1993) Idazoxan, an a, antagonist, augments fluphenazine in schizophrenic patients: a pilot study. Journal of Clinical Psychopharmacology, 13, 264-267.
15. _ & PICKAR, D. (in press) Noradrenergic systems as a target for augmenting pharmacotherapy in schizophrenia. In The New Pharmacotherapy of Schizophrenia (ed. A. Breier). Washington, DC: APA.
16. MANJI, H. (1992) G Proteins: implications for psychiatry. American Journal of Psychiatry, 149, 746-760.
17. _, HSIAO, J. H., RISBY, E. D., et al (1991) The mechanisms of action of lithium. II: effects on serotonergic and noradrenergic systems in normal subjects. Archives of General Psychiatry, 48, 513-524.
18. MELTZER, H. Y. (1989) Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology, 99 (suppl.), S18-S27.
19. 2-adrenergic drugs also bind with high affinity to a nonadrenergic site. Molecular Pharmacology, 35, 324-330.
20. 2-adrenoceptor function and sleep in man: Studies with clonidine and idazoxan. Neuropharmacology, 30, 367-372.
21. OVERALL, J. E. & GORHAM, D. E. (1961) The Brief Psychiatric Rating Scale. Psychological Research, 10, 799-812.
22. PICKAR, D. (1995) Prospects for pharmacotherapy of schizophrenia. Lancet, 345, 557-562.
23. _, OWEN, R. R., LITMAN, R. E., et al (1992) Clinical and biologic response to clozapine in patients with schizophrenia: crossover comparison with fluphenazine. Archives of General Psychiatry, 49, 345-353.
24. RICHELSON, E. & NELSON, A. (1984) Antagonism by neuroleptics of neurotransmitter receptors of normal human brain in vitro. European Journal of Pharmacology, 103, 194-204.
25. SCHOTTE, A., JANSSEN, P. F. M., MEGENS, A. A. H. P., et al (1993) Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured quantitative autoradiography. Brain Research, 631, 191-202.
26. SIMPSON, G. & ANGUS, J. S. W. (1970) A rating scale for extrapyramidal side-effects. Acta Psychiatrica Scandinavica, 212 (suppl.), 9-11.